Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors
about
sameAs
Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitorsStructure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitorsUnique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolideSJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-->C181I)RT HIV-1 mutantsSusceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitorsMichellamine B, a novel plant alkaloid, inhibits human immunodeficiency virus-induced cell killing by at least two distinct mechanismsAnalysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptaseSpecific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitorsComprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitorsActivity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replicationResistance of human immunodeficiency virus type 1 to acyclic 6-phenylselenenyl- and 6-phenylthiopyrimidinesStructure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilideHighly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolatesSubunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase.Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapySteered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT.The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT.Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not.Antiviral therapy for human immunodeficiency virus infectionsInhibition of HIV-1 reverse transcription: basic principles of drug action and resistance.Pyridin-2(1H)-ones: a promising class of HIV-1 non-nucleoside reverse transcriptase inhibitors.Characterization of a subtype D human immunodeficiency virus type 1 isolate that was obtained from an untreated individual and that is highly resistant to nonnucleoside reverse transcriptase inhibitors.The structure-activity relationships of 2,4(1H,3H)-pyrimidinedione derivatives as potent HIV type 1 and type 2 inhibitors.Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy.Restoration of human immunodeficiency virus-1-specific responses in patients changing from protease to non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.What can be Expected from Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) in the Treatment of Human Immunodeficiency Virus Type 1 (HIV-1) Infections?Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France
P2860
Q24652511-5E7AA180-77CD-4512-A9F3-44B4398F910AQ27729437-8841F45B-C941-4A70-85C2-B8B496017005Q28343461-AB352802-C2E0-4A79-A9E0-2C5D4B7AC291Q28346130-79DA9DE2-9A69-4363-B763-E7C613D88683Q28367570-14B462E8-90D1-4805-98AE-4A3A25A00B65Q28367590-9EF3B0DA-7C0A-4413-8F22-D9E754AF3BF6Q28367673-89199E1D-444B-4C89-B653-6E68417BAFFFQ28368003-F1531D78-CE1C-4E63-B8FA-FE9536127C9EQ28368032-C62BAC23-A014-4D8A-AA13-F2832BE167C4Q28368052-2113B483-45ED-43DC-817D-3A3C38300182Q28368053-F90314D0-2199-45DE-8147-CAE781838F60Q28368381-6068A457-5ABD-420C-87C3-0FFAAF815863Q28378796-0F725300-0D25-4881-B2A0-8C367122C178Q28379523-B311DB5A-B12D-44C3-84C8-918370F6610DQ33757596-BDD23C98-4269-4C54-9897-A9180D884C15Q33966329-B440E0F6-3D56-443A-A484-F7A8A3791457Q34181367-95DB294B-F293-4A12-8607-D6ABB747CC05Q35123663-2AF922F9-C2AE-4FA2-AB05-0D4E59EE3641Q35312562-35632DEE-4C57-40C6-9CA9-72683D7F69C7Q35366050-F0BF51AC-BCC0-4F50-BBC8-E437783716D4Q35917530-5A733420-E182-4C54-A677-C7F677C8E5CAQ36810076-5F614B9E-A952-40E0-A6E5-9B2448A9136FQ37730522-2DFE2B08-BF11-46B1-ADAD-AD96FE298343Q40042904-EB51BD4E-BBDF-461B-AB11-B7454ECA7006Q43956371-F9C56CB8-7702-40DF-BB2F-84EF9C7309FFQ45723089-51EDFBD8-B3BD-4652-8C25-27128853D285Q45748524-6711A80B-A449-450B-B886-E29511697B73Q57241753-33A867C0-B177-4F0D-9DEA-19A567871482
P2860
Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors
description
1992 nî lūn-bûn
@nan
1992 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Identification of the human im ...... verse nonnucleoside inhibitors
@ast
Identification of the human im ...... verse nonnucleoside inhibitors
@en
Identification of the human im ...... verse nonnucleoside inhibitors
@nl
type
label
Identification of the human im ...... verse nonnucleoside inhibitors
@ast
Identification of the human im ...... verse nonnucleoside inhibitors
@en
Identification of the human im ...... verse nonnucleoside inhibitors
@nl
prefLabel
Identification of the human im ...... verse nonnucleoside inhibitors
@ast
Identification of the human im ...... verse nonnucleoside inhibitors
@en
Identification of the human im ...... verse nonnucleoside inhibitors
@nl
P2093
P2860
P356
P1476
Identification of the human im ...... verse nonnucleoside inhibitors
@en
P2093
A J Schlabach
D J Graham
J A Wolfgang
J H Condra
R J Colonno
V V Sardana
P2860
P304
P356
10.1128/AAC.36.7.1441
P407
P577
1992-07-01T00:00:00Z